Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619682 | 0.92 | PTGER1 (0.86) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL4923018 | 0.92 | PTGER1 (0.96) | PTGER1CYP2C9TBXA2RRXRARXRB | |
| SCHEMBL5620188 | 0.92 | PTGER1 (1.00) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL4915771 | 0.91 | PTGER1 (0.85) | PTGER1CYP2C9RXRARXRBRXRG | |
| SCHEMBL5621268 | 0.90 | PTGER1 (0.69) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5621256 | 0.90 | PTGER1 (0.69) | PTGER1CYP2C9TBXA2RPTGDR2 | |
| SCHEMBL5621013 | 0.88 | PTGER1 (0.72) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL4926587 | 0.88 | PTGER1 (0.69) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5620820 | 0.86 | PTGER1 (0.72) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5620834 | 0.86 | PTGER1 (0.77) | PTGER1CYP2C9TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | claimed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | claimed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | PTGER1 323/4885CYP2C9 1/4885TBXA2R 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.